Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Verizon in Chicago: Becker’s HIT RCM

Healthcare leaders are discovering how reliable connectivity serves as the foundation for solving critical industry challenges like staffing and operational eff

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Healthcare ·
Share

Key takeaways

01

Healthcare leaders are discovering how reliable connectivity serves as the foundation for solving critical industry challenges like staffing and operational eff

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

In this episode of Healthcare On Air by Verizon, host Robin Goldsmith discusses insights from the Becker's HIT RCM conference in Chicago. The conference served as a platform for healthcare leaders and tech innovators to explore the role of connectivity in addressing healthcare challenges. Key topics included staffing shortages, operational efficiency, and technology adoption. Breakout sessions covered diverse healthcare subjects, and a roundtable discussion offered insights from adjacent industries. Verizon's unwavering commitment to healthcare innovation in the digital age invites professionals to join in and drive transformative change.

Video TranscriptExpand ↓

Hey, everyone, and welcome back to health care on air by Verizon. I'm your host, Robin Goldsmith Global Lead Global Lead for Health Innovation in strategy here at Verizon. So our Verizon healthcare team recently attended the eighth annual Becker's HIT RCM conference in Good Old Chicago where health care leaders and tech innovators from across the country and really across the globe, gather to discuss the latest trends and innovate on solutions together. Our Verizon team hosted an incredible roundtable featuring Scott Lawrence, RSVP of Global Solutions, and Gary Lynch, our global lead for Healthcare Innovation and was moderated by yours truly. With over two dozen senior level health care executives, our dedicated health care team, including Karen Finger, and Netcini discussed the critical role connectivity plays in delivering technology that addresses a whole host of challenges. To name a few staffing shortages, how to streamline operations, how to deliver an ROI when you're looking at adopting technology, and creating a basis for future technology adoption Breakout discussions focused on everything from health equity to hospital room of the future, contact centers, of course, patient experience, the digital front door, cybersecurity, and even a little bit of revenue cycle. And Scott shared critical insights from adjacent industries around tech advances that can be applied to the healthcare vertical. Verizon has committed to ongoing engagement and innovation with health care experts, as well as our partners. As we all move toward the common goal of driving meaningful and an impactful change in health care, We're all going through this digital evolution and health care together. So please come innovate with us.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

H
Healthcare
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

H
Healthcare

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512